Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

The Faroese Knee Cohort: Etiology and Long-term Implications of Trochlear Dysplasia and Patellar Dislocations.

NCT04607538 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2022-03-01
Last updated
2023-02-17

Condition(s) studied

Patellar DislocationACL InjuryMeniscus LesionTrochlear Dysplasia

Investigational drug(s) / intervention(s)

No intervention is made

No intervention is made: No intervention is made. This i an observational study.

Study summary

The investigators intend to establish a national cohort including all persons in the ages from 15-20 years old with patellar instability (PI) or a prior knee injury (ACL-ruptur or meniscus damage) . The cohort will be nicknamed "The Faroese Knee Cohort".

The overall aim is to investigate two groups.

1. The patella instability group, in which we intend to investigate the following.

* Prevalence of patellar dislocation and trochlear dysplasia in the Faroe Islands.
* Risk factors for patellar dislocations-
* Heredity of trochlear dysplasia.
* If there is a specific gene responsible for the development of trochlear dysplasia.
* The development of retropatellar artrhosis, its onset and its impact on quality of life and function,
2. Knee injury group (ACL-ruptur or meniscus injury)

* The prevalence of ACL-rupture and/or meniscus injury in this specific group in the Faroe Islands.
* The impact on quality of life and function.

Eligibility

Sex
ALL
Min age
15 Years
Max age
20 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age between 15-20 years at the start of patient enrolment. * The feeling of patellar instability, or patellar dislocation/near-dislocation. * The person has to be from the Faroe Islands. * All persons under the age of 18 must get written consent by their parents Exclusion Criteria: * Terminal illness * Mental disabilities and illness, meaning that the patient cannot independently answer the PROM´s and cooperate to the clinical investigation.

Primary outcome measure(s)

  • Severity of patellar dislocations — 1 year
    The severity of PD defined by number of PD or near-dislocations the patient experience (daily, weekly, monthly, yearly).

Trial sites (1)

FacilityCityRegionStatus
Copenhagen University Hospital Hvidovre Hvidovre Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04607538 on ClinicalTrials.gov ↗ ← All trials in Denmark